The Insight Partners published latest research report on “Malaria Treatment Market Outlook Report, Size, Share, Trends & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment, Drug Type, Route of Administration, Distribution Channel and End User”
The Insight Partners published latest research report on “Malaria Treatment Market Outlook Report, Size, Share, Trends & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment, Drug Type, Route of Administration, Distribution Channel and End User”, the global market size is projected to reach USD 2,291.49 million by 2028 from USD 1,638.27 million in 2021. The market is estimated to grow with a CAGR of 4.9% from 2022 to 2028.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00018229
Growth Strategies by the Key Players Operating in the Malaria Treatment Market:
Sept-2022: GSK plc announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission.
Jun-2022: In June 2022, at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs), Novartis announced a five-year (2021-2025) financial commitment of USD 250 million to advance R&D of new treatments to combat malaria and NTDs. This includes USD 150 million to advance the clinical development programs of its three novel malaria drug candidates to combat the emerging resistance to artemisinin. The company will also continue with activities to support the development of an optimized formulation for neonates and infants under 5kg, for whom no treatment currently exists.
Dec-2021: Drug maker Cadila Healthcare (Zydus Cadila), announced its antimalarial drug ZY19489 (MMV253), currently in development together with Medicines for Malaria Venture (MMV), received orphan drug designation from the USFDA.
Jan-2021: GSK, PATH, and Bharat Biotech (BBIL) announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.
Jan-2021: GSK and Medicines for Malaria Venture (MMV) announced that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the indication of single-dose Kozenis (tafenoquine) to pediatric populations for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.
Directly Purchase Premium Copy of Malaria Treatment Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00018229
The developments in the malaria treatment market have been characterized as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as launches, expansion, enhancement as well as relocation. Inorganic growth strategies witnessed in the market were mergers & acquisitions, partnership, collaborations, alliance, and agreement & joint ventures. These activities have paved way for expansion of business and customer base of market players.
Global Malaria Treatment Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 1,638.27 Million in 2021 |
| Market Size Value by | USD 2,291.49 Million by 2028 |
| Growth rate | CAGR of 4.9% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2021 |
| No. of Pages | 291 |
| No. of Tables | 219 |
| No. of Charts & Figures | 95 |
| Historical data available | Yes |
| Segments covered | Treatment, Drug Type, Route of Administration, Distribution Channel, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | Zydus Healthcare Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Cipla Ltd, Viatris Inc, Lupin Ltd, AdvaCare Pharma USA LLC, and VLP Therapeutics LLC |
Browse key market insights spread across 291 pages with 219 list of tables & 95 list of figures from the report, “Malaria Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Prescription Medications, Vaccines, Diagnostic Tests, and Others), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral & Intravenous), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and End User (Hospitals, Specialty Clinics, Homecare, and Others)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/malaria-treatment-market
Impact of COVID-19 on Global Malaria Treatment Market Growth:
According to the World Health Organization (WHO) report, there were an estimated 241 million cases of malaria and 627,000 malarial deaths globally in 2020. Additionally, two-thirds of these additional deaths (47,000) were linked to disruptions in the provision of malaria prevention, diagnosis, and treatment during the COVID-19 pandemic. Also, during the initial days of the pandemic, severe service disruptions caused malarial deaths in Sub-Saharan Africa. As Sub-Saharan Africa continues to carry the heaviest malaria burden accounting for ~95% of all malaria cases and 96% of all deaths in 2020 as per the estimates provided by WHO. Therefore, WHO and its partners recognize the need to ensure better and more equitable access to all health services involving malaria prevention, diagnosis, and treatment. Moreover, innovative tools also played a vital role in the treatment of malaria during the pandemic. For example, “RTS,S/AS01 (RTS,S)” is a new malaria prevention tool. Further, the WHO recommended that children living in Sub-Saharan Africa must be screened for moderate to high infection of P. falciparum
Rapid Diagnostic Tests (RDTs) to Bolster Global Malaria Treatment Market Growth:
RDTs for malaria can improve the quality of management of the disease. RDTs are proven to be highly affordable and effective for public health programs implemented in low-resource settings. RDTs are widely used in remote areas with limited access to microscopy services. As a result, there has been a rapid rise in the demand for RDTs for malaria. Several RDTs have been developed to test the presence of malaria parasites in blood samples. Identifying and successfully treating malaria in low transmission areas is critical to reduce transmission and achieve complete elimination of the disease. According to the WHO, more than 70% of malaria diagnostic testing is performed using RDTs in Africa. Many companies are engaged in developing a wide range of RDTs with high sensitivities. A few of these developments are mentioned below.
Speak To Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00018229
In November 2020, researchers from Rice University developed a simple microneedle patch similar to a bandage to detect malaria. With this development, the researchers have stepped on the path of reducing the burden of disease in countries struggling with poor health infrastructure. The microneedles loaded on the patch collect interstitial fluid, which contains several biomarkers that help in detecting malaria.
In June 2020, the Foundation for Innovative New Diagnostics (FIND) and Scanwell Health, a US-based company, partnered to develop a smartphone app that uses machine learning to read RDTs for malaria. This app would help healthcare professionals to interpret and record test results. With the expected compatibility with RDT kits and mobile devices, the app is likely to receive significant attention in low- and middle-income countries.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Malaria Diagnostics Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Drugs For Malaria Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Artesunate Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/malaria-treatment-market